Staphylococcus aureus: A Well-Armed Pathogen

Gordon L. Archer

Staphylococcus aureus is a virulent pathogen that is currently the most common cause of infections in hospitalized patients. S. aureus infection can involve any organ system. The success of S. aureus as a pathogen and its ability to cause such a wide range of infections are the result of its extensive virulence factors. The increase in the resistance of this virulent pathogen to antibacterial agents, coupled with its increasing prevalence as a nosocomial pathogen, is of major concern. The core resistance phenotype that seems to be most associated with the persistence of S. aureus in the hospital is methicillin resistance. Methicillin resistance in nosocomial S. aureus isolates has been increasing dramatically in United States hospitals and is also associated with resistance to other useful antistaphylococcal compounds. Possible ways to decrease the incidence of nosocomial S. aureus infections include instituting more effective infection control, decreasing nasal colonization, developing vaccines, and developing new or improved antimicrobials.

Staphylococcus aureus has been recognized as a major human pathogen ever since Sir Alexander Ogston [1] first proposed, in the 1880s, that it was the major cause of wound suppuration. Evidence for its virulence was shown in 1941, when Skinner and Keefer [2] reported that the mortality rate associated with S. aureus bacteremia in 122 patients at the Boston City Hospital was 82%. Furthermore, even though the introduction of β-lactam antibiotics into widespread clinical use markedly decreased mortality rates, 27% of patients with S. aureus bacteremia who were seen at the Johns Hopkins Hospital in the early 1960s died; these deaths occurred despite the fact that the patients’ infecting organisms were susceptible in vitro to the antibiotics administered [3].

Currently, S. aureus is second only to coagulase-negative staphylococci as a cause of hospital-acquired bacteremia and is the leading potentially lethal cause of these infections [4]. In addition, for 1990 to 1992, S. aureus was identified by the National Nosocomial Infections Surveillance System as the leading overall cause of hospital-acquired infections [4]. Finally, the percentage of methicillin-resistant S. aureus (MRSA) in United States hospitals rose from 2.4% in 1975 to 29% in 1991, with a MRSA rate of 38% at large (>200 beds) hospitals. Furthermore, the increase in the prevalence of MRSA and multidrug-resistant S. aureus is not just a problem in the United States but is worldwide.

Thus, S. aureus is a virulent pathogen that is currently the most common cause of infections in hospitalized patients. Its increasing resistance to antibiotics indicates that its prevalence will continue to rise. Given the number and severity of S. aureus infections in the United States and in other countries, it is important to understand the nature and pathogenesis of infections and the current strategies available for therapy and prevention.

Spectrum of Infections

Those infections or syndromes that S. aureus can cause are listed in table 1 (the diseases in boldface are those for which S. aureus is the only or the most common pathogen). It is evident that the organism can involve any organ system, and the number of infections that it causes is matched by no other single pathogen.

Pathogenesis of Infection

The five stages in the pathogenesis of S. aureus infections are (1) colonization, (2) local infection, (3) systemic dissemination and/or sepsis, (4) metastatic infection, and (5) toxinnosis. Approximately 30% of healthy individuals are colonized by S. aureus, usually in the anterior nares but also in the vagina and perianal area. The organism can be carried asymptomatically for weeks or months on mucous membranes but is only transiently carried on intact skin. Colonization is believed to precede infection. Local abscesses of skin or skin structures result when the organism is inoculated into the skin from a site of carriage. The infection can spread locally (e.g., carbuncle, cellulitis, impetigo bullosa, or wound infection) or can gain access to the blood.

Grant support: The National Institute of Allergy and Infectious Diseases (Public Health Service grant R37 AI35705).

This article is part of a series of papers presented at a satellite symposium of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. The symposium was entitled “Emerging Resistance with Gram-Positive Aerobic Infections: Where Do We Go from Here?” and was held on 14 September 1996 in New Orleans.

Reprints or correspondence: Dr. Gordon L. Archer, Division of Infectious Diseases, Department of Medicine, Medical College of Virginia, Campus of Virginia Commonwealth University, Richmond, Virginia 23298-0049.

Clinical Infectious Diseases 1998;26:1179–81
© 1998 by The University of Chicago. All rights reserved.
1058-4838/98/2605-0027$03.00
Once in the blood, the organism spreads widely to peripheral sites in distant organs, and septic shock can ensue. Without specific therapy, the mortality rate associated with disseminated infection is high. As a result of hematogenous dissemination, a number of specific staphylococcal infections can result (e.g., endocarditis, osteomyelitis, renal carbuncle, septic arthritis, or epidural abscess). Finally, even if the organism itself does not invade the bloodstream, specific syndromes can result from the local or systemic effects of specific toxins. Examples of these syndromes are toxic shock syndrome, scalded skin syndrome, and foodborne gastroenteritis. It is also apparent that certain underlying conditions or behaviors can predispose individuals to staphylococcal infections, including diabetes mellitus [3], indwelling intravenous catheters [5], intravenous drug abuse [6], and AIDS [7].

The success of the organism as a pathogen and its ability to cause such a wide range of infections are due to its extensive virulence factors. It displays a wider variety of virulence mechanisms than virtually any other human pathogen and is a model for the study of the pathogenesis of infectious diseases [8]. A list of those factors known to contribute to the virulence of the organism is shown in table 2 (the factors are grouped by their proposed pathogenetic mechanisms).

Specific factors are present that allow the organism to initially thwart opsonophagocytosis, walling off the infection to form an abscess; to invade through tissue from the initial site of infection; to induce the sepsis syndrome by promoting massive cytokine release; to move out of the blood into underlying tissue by attaching to and invading endothelial cells; and to produce specific syndromes by toxin production. There are also specific global regulatory systems, such as agr and sar, that determine which virulence factors are produced at specific times during growth and in response to the local environment [8].

It is apparent that the control of infections caused by a pathogen as virulent as \textit{S. aureus} is of major importance. The increase in the resistance of this pathogen to antibacterial agents, coupled with its increasing prevalence as a nosocomial pathogen, is of major concern.

### Table 2. Virulence factors of \textit{Staphylococcus aureus} and their proposed pathogenetic mechanisms.

<table>
<thead>
<tr>
<th>Thwart host defenses</th>
<th>Microcapsule</th>
<th>Protein A</th>
<th>Coagulase</th>
<th>Fatty acid–metabolizing enzyme</th>
<th>Leukocidin and/or γ-toxin</th>
</tr>
</thead>
<tbody>
<tr>
<td>Invade tissue</td>
<td>Proteases</td>
<td>Nucleases</td>
<td>Lipases</td>
<td>Hyaluronate lyase</td>
<td>Staphylokinase</td>
</tr>
<tr>
<td>Elicit sepsis syndrome</td>
<td>Toxic shock syndrome toxin</td>
<td>Enterotoxins</td>
<td>Cytolytic toxins (α, β, γ, and δ)</td>
<td>Induce specific toxinosis</td>
<td>Toxic shock syndrome toxin</td>
</tr>
<tr>
<td>Attach to endothelial cells and basement membrane</td>
<td>Binding proteins for fibrinogen, fibronectin, laminin, collagen, vitronectin, and thrombospondin</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Table 1. Infections or syndromes for which \textit{Staphylococcus aureus} is a prominent pathogen.

- Furuncle or carbuncle
- Impetigo bullosa
- Cellulitis
- Surgical wound infection
- Pyomyositis
- Botryomycosis
- Hospital-acquired bacteremia
- Acute or right-sided endocarditis
- Hematogenous osteomyelitis
- Septic arthritis
- Epidural abscess
- Brain abscess
- Hospital-acquired pneumonia
- Emphyema
- Septic shock
- Toxic shock syndrome
- Scalded skin syndrome
- Food-borne gastroenteritis
- Renal carbuncle

**NOTE.** Conditions in boldface are those for which \textit{S. aureus} is the sole or most common etiologic agent.
Outlook for Therapy and Prevention

There are a number of possible options for decreasing the incidence of nosocomial *S. aureus* infections and for treating infections caused by MRSA that are also resistant to other antimicrobials.

1. **Instituting more effective infection control practices.** The new Centers for Disease Control and Prevention guidelines for preventing transmission of nosocomial pathogens [12] may help prevent transmission of staphylococci within the hospital. Although this practice is unlikely to decrease the reservoir, it may decrease patients’ acquisition of *S. aureus* infection.

2. **Decreasing nasal colonization.** Since many wound infections are due to autoinoculation, decreasing nasal carriage by using either systemic or topical agents has been shown to reduce the incidence of *S. aureus* infections [13]. Studies should be performed to assess the role of widespread nasal decolonization in preventing nosocomial *S. aureus* infections.

3. **Development of *S. aureus* vaccines.** Although vaccination with various staphylococcal antigens or whole organisms has been used for some time to prevent infections in animals (such as bovine mastitis), there has been little success with vaccination for preventing human infections. However, a conjugate vaccine with *S. aureus* types 5 and 8 capsular polysaccharide coupled to *Pseudomonas* exotoxin A has been shown to be immunogenic in humans and provides some protection from challenge in animals [14]. Studies of additional antigens, including toxoids, are warranted.

4. **Development of new or improved antimicrobial agents.** With the increase in the prevalence of multidrug-resistant isolates, chemotherapy for *S. aureus* infections is becoming increasingly difficult. The pharmaceutical industry is responding either by modifying existing compounds to broaden their spectra or by developing novel compounds. The former includes modified tetracyclines (glycylcyclines), fluoroquinolones, glycopeptides, and β-lactam agents (cephems and carbapenems). The latter includes oxazolidinones and a combination drug consisting of semisynthetic derivatives of streptogramin A (dalfopristin) with streptogramin B (quinupristin). Attempts to find other unique compounds that may attack new or novel bacterial targets are also under way.

References